Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 7160.0%.

  • Northwest Biotherapeutics' EBIT Margin fell 30140600.0% to 7160.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 6927.32%, marking a year-over-year decrease of 29704900.0%. This contributed to the annual value of 4812.45% for FY2024, which is 19393600.0% down from last year.
  • Northwest Biotherapeutics' EBIT Margin amounted to 7160.0% in Q3 2025, which was down 30140600.0% from 11281.68% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' EBIT Margin ranged from a high of 1473.18% in Q1 2023 and a low of 11281.68% during Q2 2025
  • For the 5-year period, Northwest Biotherapeutics' EBIT Margin averaged around 5075.34%, with its median value being 4284.6% (2022).
  • Per our database at Business Quant, Northwest Biotherapeutics' EBIT Margin soared by 2000000000bps in 2021 and then tumbled by -78573700bps in 2025.
  • Northwest Biotherapeutics' EBIT Margin (Quarter) stood at 2871.14% in 2021, then dropped by -6bps to 3044.89% in 2022, then fell by -12bps to 3402.7% in 2023, then plummeted by -135bps to 8008.23% in 2024, then increased by 11bps to 7160.0% in 2025.
  • Its EBIT Margin was 7160.0% in Q3 2025, compared to 11281.68% in Q2 2025 and 4616.27% in Q1 2025.